Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Zyesami is Relief’s therapeutic per the Doctrine of Equivalents

https://grr.com/publications/the-doctrine-of-equivalents-in-patents/

The bad news is that NRx is now facing a lawsuit from its partner, Relief Therapeutics (OTC:RLFT.F), alleging that NRx failed to honor its obligations under the duo's collaboration agreement. NRx counters that Relief stopped funding the drug's development back in January because the company believed it would fail.

———————————————————

The conclusion, NRx Pharmaceuticals' value proposition centers on its severe COVID treatment called Zyesami (aviptadil). The company and its shareholders are hoping that the FDA will greenlight the drug soon in light of its impressive performance in the clinic. According to a recent peer-reviewed publication in the Journal of Infectious Diseases and Treatment, patients in an open-label trial at a single hospital and without randomization exhibited a ninefold survival advantage over those who received standard-of-care treatment. These initial results are highly unlikely to be enough to warrant an emergency-use authorization. But the company does appear to have a drug worth exploring further for severe COVID cases.
What's the upside potential? COVID-19 is expected to morph into an endemic respiratory illness. That means there will be a consistent need for novel coronavirus drugs -- especially for hospitalized patients with severe forms of the disease -- for a long time to come. Now, NRx still has a lot of work to do to get the drug on the market. But it does appear to be headed in the right direction. As such, this tiny drugmaker may sport a COVID-19 treatment capable of generating several hundred million dollars in sales per year for perhaps the better part of the next decade.

The bad news is that NRx is now facing a lawsuit from its partner, Relief Therapeutics (OTC:RLFT.F), alleging that NRx failed to honor its obligations under the duo's collaboration agreement. NRx counters that Relief stopped funding the drug's development back in January because the company believed it would fail.

This lawsuit could affect NRx's revenue haul for Zyesami. But the bigger picture is that the drug is showing promise in clinical trials. What's more, a sizable commercial opportunity exists for a medication capable of effectively treating covid patients suffering from respiratory failure. In short, this small-cap biotech might be gearing up for a monstrous run higher in the weeks and days ahead.

~ Zye of Relief, Y@h00 RLFTF finance conversations